The stock price of Agile Therapeutics (AGRX) fell by 10.06% in the most recent trading session. 

Why: Agile Therapeutics announced that it has reorganized and streamlined its executive leadership team to align with its business plan to promote Twirla (levonorgestrel and ethinyl estradiol) transdermal system growth. And as part of the changes, the company announced the appointment of Amy Welsh to Chief Commercial Officer effective November 1, 2022. Plus James P. Tursi, M.D. has informed the company that he will resign from the Company’s board of directors effective October 7, 2022.